共 287 条
[1]
Morgan RA(2006)Cancer regression in patients after transfer of genetically engineered lymphocytes Science 314 126-129
[2]
Dudley ME(2004)Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes Proc Natl Acad Sci USA 101 14639-14645
[3]
Wunderlich JR(2005)Targeted elimination of prostate cancer by genetically directed human T lymphocytes Cancer Res 65 9080-9088
[4]
Hughes MS(2005)Supernatural T cells: genetic modification of T cells for cancer therapy Nat Rev Immunol 5 928-940
[5]
Yang JC(2008)T-cell death and cancer immune tolerance Cell Death Differ 15 70-79
[6]
Sherry RM(1998)Peptide modification or blocking of CD8, resulting in weak TCR signaling, can activate CTL for Fas- but not perforin-dependent cytotoxicity or cytokine production J Immunol 161 6939-6946
[7]
Rosenberg SA(2004)Effector cell-derived lymphotoxin α and Fas ligand, but not perforin, promote Tc1 and Tc2 effector cell-mediated tumor therapy in established pulmonary metastases Cancer Res 64 406-414
[8]
Dudley ME(2003)Immunosensitization of resistant human tumor cells to cytotoxicity by tumor infiltrating lymphocytes Int J Oncol 22 431-437
[9]
Gade TPF(2007)ADAM10 regulates FasL cell surface expression and modulates FasL-induced cytotoxicity and activation-induced cell death Cell Death Differ 14 1040-1049
[10]
Hassen W(1998)Antitumor activity exhibited by Fas ligand (CD95L) overexpressed on lymphoid cells against Fas+ tumor cells Cancer Immunol Immunother 47 143-148